News
- BlueWillow Biologics’ Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
- H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
Contact
BlueWillow Biologics, Inc.Â
2311 Green Rd. Suite A
Ann Arbor, MI 48105
734-302-4000
734-302-9150 fax